Where peripheral T-cell lymphoma treatment is heading

Peripheral T-cell lymphomas are a group of uncommon, mostly aggressive lymphomas (about 5,000 US cases a year) that start in mature T cells. First treatment is CHOP-type chemotherapy, with brentuximab vedotin added for CD30-positive tumors, and often a stem-cell transplant; still, many people relapse. Research now focuses on drugs matched to subtype biology: epigenetic pills for angioimmunoblastic lymphoma, JAK, PI3K and ITK inhibitors, and CAR T cells designed for T-cell cancers.

• 188studies open or running
• 17phase 3 trials
• 189papers published this year

1. Now

   Nov 2026

   A PI3K pill works best in one subtypeHappened 48.0% response rate

   Duvelisib: 48.0% response overall and 62.2% in angioimmunoblastic T-cell lymphoma.

   48.0%: response rate.

   • PRIMO trial, final results

   Epigenetic and JAK pills for relapseHappened 44.3% response rate

   Valemetostat (44%) and golidocitinib (44.3%) produced responses in heavily treated people.

   44.3%: response rate.

   • JACKPOT8 trial (golidocitinib)
   • VALENTINE-PTCL01 trial

   CAR T cells for T-cell lymphomaHappened 4 of 10 complete responses

   TRBC1-targeted CAR T cells gave complete responses in 4 of 10 while sparing half of healthy T cells.

   4: of 10 had a complete metabolic response.

   • LibraT1 trial (TRBC1 CAR T cells)

2. 6 months

   by May 2027

   An ITK inhibitor moves forwardLikely 37.5% response rate

   Soquelitinib final early-phase data: 37.5% response, median survival 28.1 months; phase 3 enrolling.

   37.5%: response rate.

   • Soquelitinib phase 1/1b final results

3. 12 months

   by Nov 2027

   Adding pills to first-line chemotherapyPossible

   Alliance A051902 tests duvelisib or oral azacitidine added to CHO(E)P; due May 2027.

   • PRIMO trial, final results
   • A051902

   Two phase 3 trials at relapsePossible

   Golidocitinib (218 people) and soquelitinib (150 people) are each compared with standard choices; both due November 2027.

   • Golidocitinib phase 3
   • Soquelitinib phase 3

4. 3 years

   by late 2029

   Epigenetic drug added to CHOPLong shot

   Tucidinostat plus CHOP (224 people) is in phase 3 for newly diagnosed disease; due December 2032.

   • Tucidinostat trial

   CAR T cells aimed at CD5Long shot

   March Biosciences' MB-105 is in an early trial for CD5-positive T-cell lymphoma.

   • MB-105 trial

5. 5 years

   by late 2031

   Is a transplant needed in first remission?Possible

   An ECOG-ACRIN trial (294 people) compares stem-cell transplant with observation for people in first remission.

   • ECOG-ACRIN transplant trial

The research paths

Borrowed from other cancers

Open to join now

• Relapsed PTCL

  Golidocitinib

  Phase 3 · 51 sites

  Locations and eligibility →

• Relapsed PTCL

  Soquelitinib

  Phase 3 · 37 sites

  Locations and eligibility →

• First remission

  Transplant vs observation

  Phase 3 · 165 sites

  Locations and eligibility →

• Newly diagnosed

  Duvelisib or oral azacitidine with CHO(E)P

  Phase 2 · 96 sites

  Locations and eligibility →

• CD5-positive T-cell lymphoma

  CD5 CAR T cells

  Phase 1/2 · 12 sites

  Locations and eligibility →

See every recruiting PTCL trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

What just happened

Standard treatment today

• Newly diagnosed, CD30-positive (e.g. ALCL)Brentuximab vedotin plus CHP chemotherapy.
• Newly diagnosed, other subtypesCHOP or CHOEP; stem-cell transplant in first remission for many fit patients.
• RelapsedBelinostat, romidepsin or pralatrexate; brentuximab vedotin for CD30-positive; allogeneic transplant if possible.
• Angioimmunoblastic subtypeEpigenetic drugs (romidepsin, azacitidine) and duvelisib show the most activity.

See PTCL trials recruiting now →